← ANALYST RATINGS · TIPRANKS
Fractyl Health, Inc. (GUTS): analyst forecast and price target
Analyst consensus
Strong Buy4 Buy0 Hold0 Sell
Ratings of 4 analysts in the last 3 months · top analysts only12-month forecast
Based on 4 price targets given in the last 3 months, the average target is $44.00, the highest $96.00, the lowest $8.00. The average is +2,738.7% from the last price of $1.55.
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $4.00 → $1.50−62.5% | Hold | −3.2% | Reiterated | 17.10.26on TipRanks 08:06 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $4.00 → $1.50−62.5% | Hold | −3.2% | Reiterated | 17.10.26on TipRanks 08:06 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $4.00 → $1.50−62.5% | Hold | −3.2% | Reiterated | 17.10.26on TipRanks 08:06 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $4.00 → $1.50−62.5% | Hold | −3.2% | Reiterated | 17.10.26on TipRanks 08:06 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $4.50 → $1.50−66.7% | Hold | −3.2% | Reiterated | 17.10.26on TipRanks 08:06 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $4.00 → $1.50−62.5% | Hold | −3.2% | Reiterated | 17.10.26on TipRanks 08:06 | — | |
| Joseph Pantginis★★★★★★★★★★#243 · hits 55% · avg +24.8% | H.C. Wainwright | $96.00 → $8.00−91.7% | Buy | +416.1% | Reiterated | 16.10.26on TipRanks 12:55 | −61.6% | ↗ |
| Jason Gerberry★★★★★★★★★★#184 · hits 63% · avg +21.5% | Bank of America Securities | $24.00 | Buy | +1,448.4% | Reiterated | 12.10.26on TipRanks 07:50 | −0.2%next day −8.7% | ↗ |
| Michael Ulz★★★★★★★★★★#6183 · hits 43% · avg +0.9% | Morgan Stanley | $24.00 | Hold | +1,448.4% | Assigned | 05.10.26on TipRanks 08:35 | −7.2%next day −0.3% · 5 days −3.7% | ↗ |
| Chase Knickerbocker★★★★★★★★★★#75 · hits 59% · avg +36.2% | Craig-Hallum | $48.00 | Buy | +2,996.8% | Reiterated | 02.09.26on TipRanks 09:30 | −0.7%next day −3.7% · 5 days −8.0% | ↗ |
| Whitney Ijem★★★★★★★★★★#537 · hits 48% · avg +20.2% | Canaccord Genuity | $96.00 | Buy | +6,093.5% | Reiterated | 12.08.26on TipRanks 07:20 | −1.0%next day −5.6% · 5 days −1.0% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering Fractyl Health, Inc.
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 06.10.26: target $9.20 at a price of $4.56 (+101.8%); now: $40.00 at $1.55 (+2,480.6%).
PriceAverage targetTop analysts’ target
Recommendation trend · top analysts
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 8 | 7 | 9 | 9 | 9 | 8 |
| Buy | 1 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 18.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-1.49 (from $-1.62 to $-1.32). Last quarter: $-1.92.
Sales
Next quarter’s sales estimate — $0M (from $0M to $0M). Last quarter: $0M.
Best top-analyst consensus in the sector · Healthcare
About Fractyl Health, Inc.
- CEO: Harith Rajagopalan
- Employees: 100
- 3 Van de Graaff Drive, Burlington, MA, 01803, US
- fractyl.com
Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans. It develops Rejuva, a novel adeno-associated virus delivered pancreatic gene therapy platform that is designed to enable long-term remission of T2D and obesity by durably altering metabolic hormone function in the pancreatic islet cells of patients. Fractyl Health, Inc. was formerly known as Fractyl Laboratories Inc. and changed its name to Fractyl Health, Inc. on June 09, 2021. The company was incorporated in 2010 and is headquartered in Burlington, Massachusetts.
Data from the stock’s TipRanks forecast page, read 136 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗